TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Vivesto AB ( (SE:VIVE) ) just unveiled an update.
Vivesto AB announced positive preclinical results for Cantrixil in combination with standard treatments for Acute Myeloid Leukemia (AML), demonstrating strong effects and supporting further development. The company has filed a new international patent application to strengthen its intellectual property position and is planning to advance Cantrixil into clinical trials, while exploring partnership opportunities to optimize the development program.
More about Vivesto AB
Vivesto AB is a Swedish development company focused on offering new treatment options for hard-to-treat cancers with significant medical needs and market potential. Their project portfolio includes Cantrixil, aimed at blood cancer, and a veterinary oncology program, Paccal Vet, being evaluated for specific animal cancers. Vivesto’s shares are traded on Nasdaq Stockholm.
Average Trading Volume: 521,025
Technical Sentiment Signal: Sell
Current Market Cap: SEK121.9M
See more data about VIVE stock on TipRanks’ Stock Analysis page.